Metabolomics for rheumatic diseases: Has the time come?

Annals of the Rheumatic Diseases

Volumn 74, Issue 7, 2015, Pages 1325-1326

  Semerano, Luca ^a,b,c   Roméo, Paul Henri ^d   Boissier, Marie Christophe ^a,b,c  

^a MALIBUL and INSERM UMR1125   (France)

^b UNIVERSITÉ PARIS 13   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d Universite Paris Sud   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; BUTANE; CHOLINE KINASE; ENZYME INHIBITOR; PYRIDINIUM DERIVATIVE;

ANAEROBIC METABOLISM; BODY FLUID; CELL PROLIFERATION; EDITORIAL; HEALTH STATUS; HOMEOSTASIS; HUMAN; IMMUNOREGULATION; METABOLOMICS; NONHUMAN; OXYGEN TENSION; PRIORITY JOURNAL; PROTEOMICS; PROTON NUCLEAR MAGNETIC RESONANCE; PSORIATIC ARTHRITIS; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RNA TRANSCRIPTION; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TRANSCRIPTOMICS; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; METABOLISM;

ANIMALS; ARTHRITIS, RHEUMATOID; BUTANES; CHOLINE KINASE; ENZYME INHIBITORS; PYRIDINIUM COMPOUNDS;

EID: 84934934139     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-206618     Document Type: Editorial

References (20)

1. Nicholson JK, Lindon JC. Systems biology: metabonomics. Nature 2008;455:1054-6.
2. Veenstra TD. Metabolomics: the final frontier? Genome Med 2012;4:40.
3. Holmes E, Wilson ID, Nicholson JK. Metabolic phenotyping in health and disease. Cell 2008;134:714-17.
4. Horning EC, Horning MG. Metabolic profiles: gas-phase methods for analysis of metabolites. Clin Chem 1971;17:802-9.
5. http://www.hmdb.ca/, last consultation October 29th 2014.
6. Wishart DS, Jewison T, Guo AC, et al. HMDB 3.0 - the human metabolome database in 2013. Nucleic Acids Res 2013;41:D801-7.
7. Fuhrer T, Zamboni N. High-throughput discovery metabolomics. Curr Opin Biotechnol 2014;31C:73-8.
8. Clayton TA, Lindon JC, Cloarec O, et al. Pharmacometabonomic phenotyping and personalized drug treatment. Nature 2006;440:1073-7.
9. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006;444:860-7.
10. Fitzpatrick M, Young SP. Metabolomics - a novel window into inflammatory disease. Swiss Med Wkly 2013;143:w13743.
11. Madsen RK, Lundstedt T, Gabrielsson J, et al. Diagnostic properties of metabolic perturbations in rheumatoid arthritis. Arthritis Res Ther 2011;13:R19.
12. Kapoor SR, Filer A, Fitzpatrick MA, et al. Metabolic profiling predicts response to anti-tumor necrosis factor α therapy in patients with rheumatoid arthritis. Arthritis Rheum 2013;65:1448-56.
13. Tektonidou MG, Ward MM. Validity of clinical associations of biomarkers in translational research studies: the case of systemic autoimmune diseases. Arthritis Res Ther 2010;12:R179.
14. Schmidt M, Hartung R, Capellino S, et al. Estrone/17beta-estradiol conversion to, and tumor necrosis factor inhibition by, estrogen metabolites in synovial cells of patients with rheumatoid arthritis and patients with osteoarthritis. Arthritis Rheum 2009;60:2913-22.
15. Umetani M, Ghosh P, Ishikawa T, et al. The cholesterol metabolite 27-hydroxycholesterol promotes atherosclerosis via proinflammatory processes mediated by estrogen receptor alpha. Cell Metab 2014;20:172-82.
16. Arakaki AK, Skolnick J, McDonald JF. Marker metabolites can be therapeutic targets as well. Nature 2008;456:443.
17. Shiomi Y, Nishiumi S, Ooi M, et al. GCMS-based metabolomic study in mice with colitis induced by dextran sulfate sodium. Inflamm Bowel Dis 2011;17:2261-74.
18. Guma M, Sanchez-Lopez E, Lodi A, et al. Choline kinase inhibition in rheumatoid arthritis. Ann Rheum Dis 2015;74:1399-1407.
19. Glunde K, Serkova NJ. Therapeutic targets and biomarkers identified in cancer choline phospholipid metabolism. Pharmacogenomics 2006;7:1109-23.
20. Tzoulaki I, Ebbels TM, Valdes A, et al. Design and analysis of metabolomics studies in epidemiologic research: a primer on -omic technologies. Am J Epidemiol 2014;180:129-39.